Author + information
- Received November 5, 2009
- Revision received May 17, 2010
- Accepted May 18, 2010
- Published online July 20, 2010.
- Matthew T. Roe, MD, MHS*,* (, )
- John C. Messenger, MD†,
- William S. Weintraub, MD‡,
- Christopher P. Cannon, MD§,
- Gregg C. Fonarow, MD∥,
- David Dai, MS*,
- Anita Y. Chen, MS*,
- Lloyd W. Klein, MD¶,
- Frederick A. Masoudi, MD, MSPH†,#,
- Charles McKay, MD**,
- Kathleen Hewitt, RN††,
- Ralph G. Brindis, MD, MPH‡‡,
- Eric D. Peterson, MD, MPH* and
- John S. Rumsfeld, MD, PhD†,§§
- ↵*Reprint requests and correspondence:
Dr. Matthew T. Roe, Duke Clinical Research Institute, 2400 Pratt Street, Room 7035, Durham, North Carolina 27705
Coronary artery disease remains a major public health problem in the U.S. as many Americans experience an acute myocardial infarction (MI) and/or undergo percutaneous coronary intervention (PCI) each year. Given the attendant risks of mortality and morbidity, acute MI remains a principal focus of cardiovascular therapeutics. Moreover, 30-day mortality and rehospitalization rates for acute MI are publicly reported in an effort to promote optimal acute MI care, and aspects of MI care delivery are the focus of local, regional, and national quality initiatives (1–3). PCI remains a central therapy for patients with symptomatic coronary artery disease, particularly among patients with acute MI, and has garnered tremendous attention in the last decade with issues such as the risks and benefits of drug-eluting stents (DES) and adjunctive antithrombotic therapies.
However, there are few representative data describing contemporary patterns of care and outcomes trends for patients with acute MI and/or those undergoing PCI. This is of particular importance because the process of updating clinical practice guidelines and quality metrics for acute MI and PCI has accelerated (4). Updates or revisions to the American College of Cardiology (ACC)/American Heart Association (AHA) practice guidelines for PCI, ST-segment elevation myocardial infarction (STEMI), and unstable angina (UA)/non–ST-segment elevation myocardial infarction (NSTEMI) have been published within the last 3 years, building upon prior versions published earlier in the decade (5–7). The ACC and AHA have also published performance measures to direct quality assessment and improvement activities (8). However, data are lacking on current guideline adherence as well as on trends in the quality of care and outcomes for the large population of patients in the U.S. with symptomatic coronary artery disease.
Large-scale, national clinical registries provide an important opportunity to evaluate current clinical practice. The American College of Cardiology's National Cardiovascular Data Registry (NCDR) comprises a suite of programs involving >2,400 hospitals in the U.S. (www.ncdr.com). We analyzed the NCDR Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get With The Guidelines (AR-G) and Catheterization PCI (CathPCI) databases to characterize recent trends in treatment and outcomes among patients with acute MI and those undergoing PCI. More specifically, we sought to evaluate patient and hospital characteristics, rates of guideline adherence, procedural details, and in-hospital outcomes related to acute MI and PCI care over the last several years.
The NCDR AR-G registry is a national, voluntary quality improvement registry program that is a partnership of the ACC and AHA and includes data on the in-hospital treatment of patients with acute MI, both STEMI and NSTEMI (9). The cohort analyzed for AR-G for this study includes all 131,980 STEMI and NSTEMI patients enrolled from approximately 250 participating centers from the inception of AR-G in January 2007 through June 2009.
The NCDR CathPCI registry is a national quality improvement program focused on diagnostic cardiac catheterization and PCI, and is a partnership between the ACC and the Society for Cardiovascular Angiography and Interventions. The CathPCI registry includes in-hospital data on patients undergoing cardiac catheterization and PCI procedures (10). The analytic cohort from CathPCI for this study includes all 1,708,247 patients who underwent PCI in January 2005 through June 2009; there were 436 participating hospitals in quarters 1 and 2, 2005, and 959 hospitals in quarters 1 and 2, 2009.
Comparisons of patient characteristics, treatments, procedural complications, and in-hospital outcomes were performed between the first 6 months and the last 6 months of the respective analysis time periods for the AR-G (quarters 1 to 2, 2007 vs. quarters 1 to 2, 2009) and CathPCI (quarters 1 to 2, 2005 vs. quarters 1 to 2, 2009) registries. In the AR-G registry cohort, the temporal comparisons were stratified by type of MI (STEMI or NSTEMI). In the CathPCI registry cohort, the comparisons were stratified by acute coronary syndrome (ACS [UA, NSTEMI, and STEMI]) and non-ACS (elective PCI) patients. Median values with interquartile ranges (25th, 75th percentiles) were used to describe continuous variables, and percentages were reported for categorical variables. Continuous and ordinal categorical variables were compared using the stratum-adjusted Wilcoxon rank-sum test, and nominal categorical variables were compared using the stratum-adjusted chi-square test.
For the AR-G registry, composite performance scores and defect-free care scores were determined separately for STEMI and NSTEMI patients, as detailed in the Online Appendix(8,11,12). The p values for the temporal trends of composite performance scores and defect-free care scores were obtained using linear regression with time as an ordinal independent variable.
Temporal changes in clinical outcomes (adjusted in-hospital mortality and unadjusted major bleeding) were analyzed by quarter separately for STEMI and NSTEMI patients for the 2.5-year analysis time period for the AR-G registry cohort. The AR-G in-hospital mortality model was utilized to calculate adjusted mortality rates for the NSTEMI and STEMI populations (13). For the CathPCI registry, temporal changes in adjusted in-hospital mortality and unadjusted periprocedural vascular and bleeding complications were analyzed by quarter separately in the ACS and non-ACS populations for the 4.5-year analysis time period. The CathPCI risk-adjusted in-hospital mortality model was utilized to calculate adjusted in-hospital mortality rates for the ACS and non-ACS populations (14). The p values for the temporal trends of in-hospital outcomes and complications were obtained by modeling time as an ordinal independent variable using the logistic generalized estimating equations method with an exchangeable working correlation matrix to account for within-hospital clustering because patients at the same hospital are more likely to have similar responses relative to patients at other hospitals (i.e., within-center correlation for responses) (15).
A p value of <0.05 was considered statistically significant for all tests. All analyses were performed using SAS software (version 9.2, SAS Institute, Cary, North Carolina).
Among the AR-G registry cohort, there was an increase in the proportion of patients with cardiac risk factors of current smoking, hypertension, and hyperlipidemia (Table 1).Among ACS patients in the CathPCI registry cohort, there was an increase in the proportion of patients with cardiac risk factors and signs of heart failure on presentation and a decrease in the proportion of patients with a history of prior MI, prior PCI, or prior coronary artery bypass graft surgery (Table 2).Furthermore, the proportion of ACS patients in the CathPCI registry cohort with UA decreased, whereas the proportions of patients with NSTEMI and STEMI increased (Table 2).
Treatment and procedural details
In the AR-G registry, increases in the use of anticoagulants were demonstrated in both STEMI and NSTEMI patients, whereas there were decreases in the use of acute beta-blockers and glycoprotein IIb/IIIa inhibitors (Table 3).Among NSTEMI patients, decreased rates of overdosing of unfractionated heparin, low-molecular-weight heparin (LMWH), and glycoprotein IIb/IIIa inhibitors were observed. Among STEMI patients, the overall proportion of eligible patients who received reperfusion therapy increased, paralleling an increase in the proportion of reperfused patients who underwent primary PCI as well as an increase in the proportion of patients who met quality benchmarks for rapid reperfusion times.
The use of early cardiac catheterization within 48 h and the use of revascularization procedures increased in NSTEMI patients. Increases in the use of discharge statins and clopidogrel, as well as cardiac rehabilitation referral, were observed for both STEMI and NSTEMI patients (Table 3).
In the CathPCI registry cohort, patterns of antithrombotic agent (anticoagulant and antiplatelet medications) use significantly changed among both ACS and non-ACS patients, with increasing use of bivalirudin and decreasing use of unfractionated heparin, glycoprotein IIb/IIIa inhibitors, and LMWH (Table 4).The complexity of PCI procedures appeared to increase, with a larger proportion of patients with type C lesions treated during PCI in both the ACS and non-ACS cohorts at the end of the analysis time period. Significant decreases in the use of DES were demonstrated in both ACS and non-ACS patients, but increases in the use of new DES types (everolimus and zotarolimus) were also observed.
The acute MI composite performance scores in the AR-G registry were high, but increased from 90% to 94% among STEMI patients and from 90% to 92% among NSTEMI patients (Fig. 1A).The defect-free composite care scores were lower, but significant improvements in these scores were demonstrated in both STEMI (50% to 69%) and NSTEMI patients (58% to 66%) (Fig. 1B).
Among patients in the AR-G registry, risk-adjusted in-hospital mortality rates decreased from 6.2% to 5.5% among STEMI patients and decreased from 4.3% to 3.9% among NSTEMI patients during the study period (Fig. 2A).Unadjusted major bleeding rates did not significantly change, remaining between 11.3% and 11.0% for STEMI patients and between 10.2% and 9.0% for NSTEMI patients (Fig. 2B).
In the CathPCI registry, there were decreases in unadjusted composite vascular complications (Fig. 3A)and composite bleeding complications (Fig. 3B) among ACS and non-ACS patients. Risk-adjusted in-hospital mortality did not change substantially among ACS patients (2.2% to 2.0%) and non-ACS patients (0.5% to 0.5%) during the study period (Fig. 3C).
The goal of this report was to evaluate contemporary clinical practice, as well as recent trends in treatments and outcomes, among acute MI and PCI patients. Analyzing data from 2 large-scale national registry programs of the NCDR, the most notable findings were improvements in the provision and timeliness of reperfusion therapy for STEMI patients and in the use of guideline-recommended medications for both STEMI and NSTEMI, and a decrease in PCI-related procedural and vascular complications despite an increase in procedural complexity. The results are generally encouraging with regard to key processes in the care of acute MI and PCI patients and the translation of evidence into practice, yet also highlight areas of need for quality improvement, opportunities to improve patient outcomes, and targets for additional research.
Some of the most encouraging findings of this study were the significant increases in the timeliness of acute MI patient presentation after symptom onset, in the proportion of eligible STEMI patients receiving reperfusion therapy, and in the timeliness of reperfusion therapy for STEMI. These findings may, in part, reflect the impact of local, regional, and/or national quality improvement initiatives that have gained an increasing foothold in the U.S. in recent years. Such initiatives have focused on patient education and awareness of acute MI symptoms in the community, reducing door-to-balloon times for primary PCI and improving systems of care for acute MI patients (1–3).
Building upon improvements in treatment for acute MI patients from earlier analyses, we have demonstrated further improvements in the rates of guidelines- and performance measure-recommended medication adherence over a relatively short period of time at the end of the last decade, with very high rates of utilization of aspirin, clopidogrel, statins, beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers, as well as increased rates of smoking cessation counseling and referral for cardiac rehabilitation among eligible patients (5–8,16). Furthermore, significant reductions in the rate of overdosing of antithrombotic agents were demonstrated among NSTEMI patients—a finding that highlights a new area of focus in the acute MI performance measures (8,17). The improvements in care demonstrated among NCDR-participating hospitals highlight the potential benefit of voluntary participation in clinical registries as regular data feedback and focused site performance improvement activities have been shown to result in greater improvements in guidelines adherence compared with pay-for-performance incentive programs (18). The AR-G registry participants, for example, receive quarterly feedback reports that profile and benchmark composite performance scores and defect-free care scores, medication overdosing, and other metrics of guidelines adherence for acute MI patients, whereas CathPCI participants receive quarterly reports focused upon procedural medications, details, and complications. However, the results from this report also reinforce the need for ongoing quality improvement efforts as there are still gaps in the provision of guideline-recommended medications among eligible acute MI patients, and further reductions in procedural complications can still be realized.
While providing a benchmark for the future evaluation of care processes and outcomes associated with acute MI and PCI procedures, the results from this report highlight several unique temporal changes in care among patients undergoing PCI. First, periprocedural antithrombotic treatment strategies during PCI have significantly changed over the last several years, with decreased use of glycoprotein IIb/IIIa inhibitors and increased use of bivalirudin. This fairly rapid shift in clinical practice is concordant with the most recent guideline updates for management of acute MI and patients undergoing PCI, which reflect new data from clinical trials evaluating anticoagulation strategies aimed at reducing bleeding (5–7,19,20). Second, while we verified results from other publications by demonstrating declining rates of DES utilization in patients undergoing PCI for both ACS and non-ACS from 2005 to 2009, we have shown the unique finding of recent widespread incorporation of new DES technologies among patients receiving a DES in the CathPCI registry (21). Finally, the complexity of PCI procedures appears to have increased with time, but temporal reductions in vascular and bleeding complications were also demonstrated, so additional studies are needed to understand how data feedback from the CathPCI registry and changes in procedural techniques and management have influenced the results and safety of PCI.
Mortality risk-adjustment models recently have been derived and validated for both the AR-G and CathPCI registries based on contemporary patient and procedural data reported in this paper, are currently being used to report risk-adjusted mortality in quarterly site feedback reports for hospitals participating in the AR-G and/or CathPCI registries, and will be published separately (13,14). Thus, further studies from these databases will be positioned to evaluate temporal trends in risk-adjusted mortality among acute MI and PCI patients in this new decade and will complement prior analyses that demonstrated sustained reductions in risk-adjusted mortality among acute MI patient across prior decades (22). Additionally, site-specific feedback on adjusted mortality in the AR-G and CathPCI registries will complement current risk-adjusted mortality feedback from claims data for hospitals seeking to optimize their care of acute MI and PCI patients. Finally, the NCDR risk-adjustment models will inform and facilitate comparative effectiveness research efforts such as the recently awarded Grand Opportunities grant, which will fund the combined ACC and Society of Thoracic Surgeons effort designed to evaluate the impact of percutaneous versus surgical revascularization procedure.
The results of this report should be interpreted in the context of several considerations. First, the data presented were intended to provide a fairly general representation of current practice and recent trends; as such, these data are largely descriptive without adjustment for case mix, so conclusions based on observed associations should be made with caution. Second, participation in the AR-G and CathPCI registries is largely voluntary, so the results may not be generalizable to all U.S. hospitals because “high performing” centers may preferentially participate, and non-PCI hospitals are not represented in the CathPCI registry and are under-represented in the AR-G registry. However, both registries have broad geographic participation, and are the largest clinical registries for acute MI and PCI in the U.S. Nonetheless, hospital participation varied in the CathPCI registry from 436 participating hospitals in quarters 1 and 2, 2005, compared with 959 hospitals in quarters 1 and 2, 2009, whereas a relatively stable group of 250 hospitals participated in the AR-G program during the analysis time period. This finding may partly explain the significant differences in patient characteristics such as race and prior revascularization from the beginning to the end of the analysis period for the CathPCI registry. These differences in patient characteristics may have influenced the treatment, procedural, and outcome results presented in this analysis. Finally, only in-hospital outcomes and treatments are profiled in AR-G and CathPCI so longer-term outcomes could not be assessed.
The contemporary profile of care patterns for patients with acute MI and those undergoing PCI indicates that patient and procedural characteristics have changed over a relatively short time, while significant improvements in the receipt and timeliness of reperfusion therapy for STEMI, in the overdosing of antithrombotic therapies, in the safety and results of PCI procedures, and in composite measures of acute MI care were also demonstrated. These results serve as a benchmark for the ongoing evolution of strategies designed to promote evidence-based and safe care for acute MI and PCI, and also highlight the importance of accurately profiling differences in patient and procedural characteristics to provide comparable feedback on clinical outcomes to hospitals across the U.S.
Dr. Roe has received research funding from Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis, and Merck/Schering-Plough; and consulting fees/honoraria from GlaxoSmithKline, Novartis, Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis, Merck/Schering-Plough, and AstraZeneca. Dr. Messenger is a Principal Investigator for the Resolute substudy, Medtronic Co. Dr. Cannon has received research grants/support from Accumetrics, AstraZeneca, GlaxoSmithKline, Intekrin Therapeutics, Merck, and Takeda; is on the advisory board of Bristol-Myers Squibb/Sanofi, Novartis, and Alnylam; and is a clincal advisor with equity in Automedics Medical Systems. Dr. Fonarow has received honoraria from Merck and Bristol-Myers Squibb/Sanofi. Dr. Klein is on the Speakers' Bureau of Pfizer, Lilly, and Daiichi-Sankyo. Dr. Masoudi has contracts with the ACCF and the Oklahoma Foundation for Medical Quality. Dr. McKay is an ACC-NCDR Senior Medical Officer. Dr. Peterson has received research support from Bristol-Myers Squibb/Sanofi, Merck/Schering-Plough, Lilly, and Johnson & Johnson. Dr. Rumsfeld is the Chief Science Officer for the NCDR.
For the calculation of acute MI performance measure composite scores and defect-free care composite scores, please see the online version of this article.
|Increasedreperfusion therapy use for eligible STEMI patients, from 90.8% to 93.8%.|
|IncreasedSTEMI door-to-balloon times ≤90 min for primary PCI, from 64.5% to 88.0%.|
|Decreasedoverdosing of unfractionated heparin (27.2% to 21.0%), low-molecular-weight heparin (18.0% to 15.1%), and glycoprotein IIb/IIIa inhibitors (10.7% to 8.8%) among NSTEMI patients.|
|Improvedacute MI composite performance measure scores (89.9% to 94.4%) and defect-free care composite performance measure scores (49.9% to 69.4%) among STEMI patients.|
|Improvedacute MI composite performance measure scores (89.6% to 92.3%) and defect-free care composite performance measure scores (58.2% to 66.2%) among NSTEMI patients.|
Abbreviations as in Tables 1 and 2.
|For ACS patients, decreaseduse of periprocedural glycoprotein IIb/IIIa inhibitors (57.3% to 44.4%) and increaseduse of bivalirudin (27.1% to 43.4%).|
|For non-ACS patients, decreaseduse of periprocedural glycoprotein IIb/IIIa inhibitors (38.5% to 21.5%) and increaseduse of bivalirudin (37.8% to 57.3%).|
|Higher procedural complexity, with an increasedproportion of ACS (43.3% to 46.9%) and non-ACS patients (33.7% to 38.7%) with type C lesions treated during PCI.|
|Decreaseduse of drug-eluting stents in both ACS (83.6% to 66.5%) and non-ACS patients (85.7% to 73%).|
|Decreaseduse of sirolimus and paclitaxel stents (100% to 34.9%) with introduction new stent types (everolimus and zotarolimus) among patients receiving a drug-eluting stent.|
Abbreviations as in Tables 1 and 2.
|Significant decreasesin risk-adjusted in-hospital mortality among STEMI patients (6.2% to 5.5%) and NSTEMI patients (4.3% to 3.9%).|
|No changein unadjusted in-hospital major bleeding among STEMI (11.3% to 11.0%) and NSTEMI (10.2% to 9.0%) patients.|
Abbreviations as in Table 1.
Treatments, Trends, and Outcomes of Acute Myocardial Infarction and Percutaneous Coronary Intervention
The NCDR ACTION Registry-GWTG is a program of the American College of Cardiology and the American Heart Association that receives funding from the Merck/Schering-Plough Corporationand Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership. The CathPCI registry does not receive external funding. For complete author disclosures, please see the end of this paper.
- Abbreviations and Acronyms
- American College of Cardiology
- acute coronary syndromes
- Acute Coronary Treatment and Intervention Outcomes Network
- American Heart Association
- ACTION Registry–Get With The Guidelines
- catheterization and percutaneous coronary intervention
- drug-eluting stent
- low-molecular-weight heparin
- National Cardiovascular Data Registry
- non–ST-segment elevation myocardial infarction
- percutaneous coronary intervention
- unstable angina
- Received November 5, 2009.
- Revision received May 17, 2010.
- Accepted May 18, 2010.
- American College of Cardiology Foundation
- Nissen S.E.,
- Brush J.E. Jr..,
- Krumholz H.M.
- Jacobs A.K.,
- Antman E.M.,
- Faxon D.P.,
- Gregory T.,
- Solis P.
- Califf R.M.,
- Peterson E.D.,
- Gibbons R.J.,
- et al.
- King S.B. III.,
- Smith S.C. Jr..,
- Hirshfeld J.W. Jr..,
- et al.
- Antman E.M.,
- Hand M.,
- Armstrong P.W.,
- et al.
- Anderson J.L.,
- Adams C.D.,
- Antman E.M.,
- et al.
- Krumholz H.M.,
- Anderson J.L.,
- Bachelder B.L.,
- et al.
- Peterson E.D.,
- Roe M.T.,
- Rumsfeld J.S.,
- et al.
- Brindis R.G.,
- Fitzgerald S.,
- Anderson H.V.,
- Shaw R.E.,
- Weintraub W.S.,
- Williams J.F.
- Roe M.T.,
- Chen A.Y.,
- DeLong E.R.,
- et al.
- Peterson E.D.,
- Dai D.,
- DeLong E.R.,
- et al.
- Liang K.Y.,
- Zeger S.L.
- Roe M.T.,
- Chen A.Y.,
- Cannon C.P.,
- et al.